Skye Bioscience to Join Upcoming Healthcare Investment Events

SAN DIEGO, Aug. 26, 2024 - Skye Bioscience, Inc. (Nasdaq: SKYE), a biopharmaceutical company in the clinical trial phase, is dedicated to discovering innovative therapeutic pathways for metabolic health. The company has announced its participation in several upcoming healthcare investment conferences. These include Morgan Stanley's meeting on Friday, September 6 in New York, Cantor Global Healthcare Conference on Thursday, September 19 where they will present at 8:35 am ET and hold one-on-one meetings, and the Bank of America World Medical Innovation Forum on Tuesday, September 24 in Boston which will feature a panel discussion and one-on-one meetings.

Skye Bioscience is particularly focused on developing next-generation molecules that modulate G-protein coupled receptors. Their strategy is to target biologic mechanisms with substantial human proof for creating first-in-class therapeutics that offer clinical and commercial uniqueness. An important milestone for the company is the commencement of a Phase 2 clinical trial in August 2024 for nimacimab, a negative allosteric modulating antibody that inhibits CB1 peripherally. This trial aims to compare the effectiveness of nimacimab as a monotherapy and in combination with a GLP-1R agonist (Wegovy®) in treating obesity.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!